FDA Affirms Tirzepatide Shortage Resolved, Sets Transition Period for Compounding
The FDA issued a declaratory order affirming that the shortage of tirzepatide (Munjaro, Zepbound; Eli Lilly and Company) injection products is resolved. As a result, compounders will have a limited grace period during which the FDA will not take legal …